SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending due to recent U.S. regulatory updates, including NOAA's modernization of deep-sea mining permits, signaling a faster path to commercial recovery for companies like TMC. The community is highly bullish, discussing the potential for a short squeeze amidst high short interest and viewing critical deep-sea minerals as a national security priority. This policy shift is driving significant investor anticipation for expedited permits and a re-evaluation of the sector's long-term value.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending following news of a strategic site acquisition for AI/High-Performance Computing data centers and a notable investment from SoftBank, signaling its strong pivot beyond traditional Bitcoin mining. The community is actively discussing CIFR's growing role in providing critical computational infrastructure, highlighting its robust contracts with major tech players and potential for future expansion in a high-demand sector.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending sharply higher following President Trump's announcement of a "framework" deal for Greenland, leading to a pause in European tariffs and igniting a significant relief rally. The community is actively debating whether this is a genuine breakthrough or another calculated "TACO Trade" designed to induce market volatility. Despite the immediate surge, underlying skepticism persists regarding the deal's specifics and broader geopolitical stability.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging after a pivotal arbitration win against Repsol, which the community views as a major de-risking event and potential precursor for resolving other legal challenges. This positive news, coupled with high short interest, is fueling strong short squeeze speculation and highlighting the company's position as a rapidly expanding LNG exporter amidst robust global demand.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending amid intense debate over an anticipated TikTok acquisition deal closing, which is fueling bullish calls for a significant rebound. This optimism clashes with widespread community concerns about Oracle's substantial debt for AI infrastructure, potential lawsuits, and the perceived financial risks of its OpenAI partnerships, leading many to predict further stock depreciation. The discussion highlights broader uncertainty in the capital-intensive AI cloud sector and its impact on major tech players.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel (INTC) is experiencing a significant rally leading up to its earnings report, driven by analyst upgrades and widespread community speculation regarding potential major partnerships like Apple and substantial US government contracts for its foundry services. Many investors are pointing to Intel's strategic importance in advanced chip manufacturing and a renewed focus on product leadership, with some anticipating a continued upward trend despite others warning of a "sell the news" event post-earnings.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst high anticipation for a significant Siri overhaul and an innovative AI-powered wearable, which bulls see as a major catalyst for growth and a reason to buy an oversold stock. However, the community remains divided, with skeptics questioning Apple's true AI innovation and current valuations, leading to volatile price action and debate about its near-term direction despite strong upcoming earnings expectations.

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Mimedx Group Inc

MiMedx Group is trending due to upcoming CMS policy changes expected to significantly alter reimbursement for wound care products, prompting a polarized community discussion. While many voice strong concerns over potential revenue losses and allegations of past billing improprieties, others believe MiMedx's clinically validated products and solid financial standing will enable it to thrive by capturing market share from competitors impacted by the broader regulatory crackdown on industry fraud. This pivotal moment has investors fiercely debating whether the company faces an existential threat or a unique opportunity for market leadership.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to significant open-market share purchases by Chairman and CEO Ryan Cohen over recent days, with another board member also increasing their stake. This decisive insider buying is fueling widespread community discussion, with many interpreting it as a strong signal of leadership conviction and a potential indication that the stock has found a bottom, reigniting expectations for future movement.

Pelican Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Pelican Acquisition Corp.

Pelican Acquisition Corp. ($PELI) is currently trending following its definitive merger agreement to form Greenland Energy Company, with an anticipated ticker change to $GLND. The community is actively discussing the substantial potential for oil and energy resources in Greenland, fueled by speculative ties to past geopolitical interest and a growing "meme stock" narrative. Many view this early-stage play as an "under the radar" opportunity with considerable long-term growth prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year.</li><li>Moderna was in focus after updated cancer vaccine data, while Novavax drew attention following its Pfizer licensing deal.</li><li>Retail sentiment on Stocktwits was 'extremely bullish' for both stocks, with message activity sharply higher over the past year.</li></ul><p>Wall Street is&nbsp;a bit&nbsp;split on Moderna and Novavax, with analysts favoring upside in one name even as the other has outperformed over the past year.</p><h2 class="st-heading-2"><strong>Analysts Favor Novavax Over Moderna</strong></h2><p>Koyfin data shows analysts assigning greater upside to Novavax than Moderna based on consensus price targets.</p><p>Moderna shares were last trading around $49.81 on Wednesday, but Wall Street’s expectations remain cautious. The stock’s average 12-month price target is $37.40, a 25% downside from current levels. Among the 24 analysts covering the company, the overall view sits at ‘Hold’, with two ‘Strong Buy’, two ‘Buy’, 17 ‘Hold’, one ‘Sell’, and two ‘Strong Sell’ ratings, giving Moderna an overall ‘Hold’ rating.</p><p>Meanwhile, Novavax last closed at $9.9 on Wednesday, and analysts see room for gains. The stock’s average 12-month price target of $12.89 points to a 30% upside&nbsp;from current levels. Among the nine analysts tracking the company, five rate it ‘Buy’, one ‘Hold’, one ‘Sell’, and two ‘Strong Sell’, giving Novavax an overall ‘Buy’ rating.</p><p>Over the past 12 months,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax shares</a>&nbsp;have been up about 12%, while&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> has gained roughly 39%.</p><h2 class="st-heading-2"><strong>Moderna Faces Analyst Caution</strong></h2><p>On Tuesday,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-still-worth-37-less-after-cancer-vaccine-data-bof-a-s-new-price-target-keeps-retail-traders-cautious/cmUDauIR4OV">Bank of America Securities raised its price target to $27 from $24</a> while keeping an ‘Underperform’ rating, implying a 37% downside based on the stock’s prior close near $43.</p><p>The update followed the release of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">five-year follow-up data</a> for Moderna’s personalized cancer vaccine Intismeran Autogene, developed with Merck and used alongside Keytruda in patients with high-risk melanoma. Moderna and Merck said patients receiving the combination showed a 49% lower risk of cancer recurrence or death compared with Keytruda alone.&nbsp;</p><p>Earlier this month, UBS downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $34 from $40, implying about 32% downside from its last close.&nbsp;</p><p>Moderna expects regulatory approvals this year for a standalone flu vaccine and a COVID-19/flu combination shot, though not in time for the 2026 respiratory season, with a potential boost in 2027. The company also expects key trial data in 2026, including late-stage norovirus results and mid-stage melanoma data.&nbsp;</p><h2 class="st-heading-2"><strong>Novavax In Focus</strong></h2><p>This week, Novavax&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-nvax-stock-rising-premarket-pfizer-matrix-m-deal/cmUumrjR4aq">signed a non-exclusive licensing deal with Pfizer</a> for up to two disease areas using its Matrix-M adjuvant. The deal includes a $30 million upfront payment, as well as the possibility of up to $500 million in development and sales milestones, and tiered royalties in the high mid-single-digit range.&nbsp;</p><p>That deal followed Novavax handing over U.S. and European rights to its Covid-19 vaccine candidate Nuvaxovid to Sanofi in November for undisclosed upfront payments and possible milestones. The deal also opens the door&nbsp;to future royalties. Novavax also has deals with Takeda and the Serum Institute of India.</p><p>Novavax has pushed its profitability target to 2028 as Covid-19 vaccine demand remains under pressure, while activist investor Shah Capital, which holds about 8.3%, has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-stock-faces-retail-backlash-as-shah-capital-warns-of-proxy-fight-and-presses-for-a-sale/cLPBFk7REdt">urged the board to review strategic alternatives</a>, including a potential sale.</p><h2 class="st-heading-2"><strong>Regulatory Backdrop</strong></h2><p>Uncertainty over regulatory approval also looms for both companies. Shares of Moderna and Novavax fell in December after an FDA memo to staff, which did not name a manufacturer, warned of safety problems with vaccines that could lead to tougher approval standards.</p><p>Novavax’s COVID-19 vaccine has full FDA approval with age- and risk-level-based restrictions, while Moderna's COVID-19 vaccines have full licensure across broader age groups.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment toward Moderna was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 3% and message activity more than doubling over the past 12 months.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_124327497e.webp" alt="mrna ss.png" width="971" height="142"><figcaption>MRNA sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure><p>On the other hand, retail sentiment toward Novavax was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 5% and message activity surging more than 600% over the past 12 months.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_ec285c2653.webp" alt="nvax ss.png" width="969" height="138"><figcaption>NVAX sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now?

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine safety.

Equity

Intel, Moderna, TMC, Microsoft And Lucid: Why These 5 Stocks Are On Investors' Radars Today

INTC, MRNA, TMC, MSFT, LCID were among the stocks seen trending on Wednesday, Jan. 21, 2026.read more...

Why Moderna Stock Surged Today

Key PointsModerna's and Merck's partnership could help to advance cancer care...

Moderna Stock Skyrockets To 52-Week High: What's Behind The Surge?

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long term results from a cancer therapy study.read more...

Moderna (NASDAQ:MRNA) Sets New 1-Year High - What's Next?

Moderna (NASDAQ:MRNA) Sets New 52-Week High - Here's Why...

Promising Biotech Stocks To Consider - January 21st

Moderna, ImmunityBio, Danaher, Vertex Pharmaceuticals, argenex, BioNTech, and Legend Biotech are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks...

Can HCA Q4 Earnings Withstand Higher Costs & Lower Outpatient Cases?

HCA Healthcare heads into Q4 earnings with solid admission and revenue growth, but rising costs and declining outpatient surgery cases cloud the odds of a beat.

Sumitomo Mitsui Trust Group Inc. Reduces Position in Moderna, Inc. $MRNA

Sumitomo Mitsui Trust Group Inc. reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 86.1% in the 3rd quarter, according to the company in its most recent 13F filing with...

<ul class="summary-bullets"><li>BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares.</li><li>The update followed the release of five-year follow-up results for the Intismeran vaccine used alongside Keytruda in melanoma patients.</li><li>Moderna and Merck said additional data from the study will be shared at an upcoming medical meeting.</li></ul><p>Moderna Inc. shares were in focus on Wednesday after Bank of America Securities (BofA) raised its price target on the stock following new long-term data from the company’s experimental skin cancer vaccine developed with Merck, while keeping a bearish rating in place.</p><p>Merck shares rose 0.6% in regular trading before slipping 0.6% after hours, while Moderna climbed 2.8% during the session and edged 0.2% lower in extended trading.</p><h2 class="st-heading-2"><strong>Price Target Raised, Rating Maintained</strong></h2><p>BofA raised its price target on Moderna to $27 from $24 and reiterated an ‘Underperform’ rating on the shares. However, based on Moderna’s last closing price of $43, the updated target&nbsp;still implies about a 37% downside.</p><p>The firm said the increase followed the release of five-year data for Intismeran Autogene, Moderna’s personalized cancer vaccine, used in combination with Merck’s Keytruda in patients with high-risk melanoma.</p><p>While noting some upside potential, the brokerage pointed to challenges seen in similar combination treatments in the past, logistical challenges, and a “higher bar for success.” BofA said the higher price target reflects increased sales expectations for the vaccine in patients who have undergone surgery for melanoma.</p><h2 class="st-heading-2"><strong>Five-Year Skin Cancer Results</strong></h2><p>Moderna and Merck said the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">latest follow-up</a> showed the vaccine combination continued to help patients remain cancer-free for longer than Keytruda alone.</p><p>After five years, patients who received the combination saw a 49% lower risk of the cancer returning or leading to death than those treated with Keytruda by itself. The companies said the findings build on earlier updates shared at the two-year and three-year marks. Moderna and Merck also said they plan to share additional follow-up results at an upcoming medical meeting.</p><h2 class="st-heading-2"><strong>Oncology Pipeline Progress</strong></h2><p>“Now with five years of follow-up data, today's results highlight the potential of a prolonged benefit of the intismeran autogene and Keytruda combination in patients with resected high-risk melanoma,” said Kyle Holen, Moderna’s head of oncology development.</p><p>Holen said the company continues to invest in cancer research and is preparing for several upcoming milestones, including results from a late-stage melanoma study being run with Merck, as well as progress across eight ongoing studies in different cancer types. Meanwhile, Merck’s head of oncology, Marjorie Green, said the long-term results are encouraging for patients&nbsp;at high risk of the disease returning after surgery.</p><p>Moderna said it is continuing to expand its cancer treatment work alongside its vaccine business. The company and Merck are currently running or enrolling studies across several cancers, including lung, bladder, kidney, and melanoma, as part of their joint development program for the vaccine.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment was ‘neutral’ for Moderna and ‘bearish’ for Merck, with both seeing ‘normal’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_65694a07b3.webp" alt="mrna ss.png" width="969" height="140"><figcaption>MRNA sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/mrk_ss_png_42eb55ab2c.webp" alt="mrk ss.png" width="961" height="141"><figcaption>MRK sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> has risen 26% over the past 12 months, while Merck’s stock has jumped 16% over the same period.&nbsp;On Wall Street, analysts are largely neutral on MRNA, according to Koyfin data: 17 out of 24 analysts covering the stock recommend a ‘hold’ rating, while four have a ‘buy’ or ‘strong buy’ conviction, and the rest have a ‘sell’ rating. Their consensus price target of $​​36.75 leaves MRNA trading at a more than 14% premium.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious

BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges.

Moderna Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or causing death by nearly half compared with Keytruda alone.read more...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Stocktwits

Stocktwits Polls

Investors are highly optimistic following strong five-year follow-up data for its partnered skin cancer vaccine, showing significant improvements in recurrence-free survival.

A powerful surge has trapped short sellers, leading to a scramble for cover as the stock rockets higher, eliciting celebratory taunts from long positions.

Bulls are confidently predicting the stock will reach or surpass $100, with many foreseeing a return to $200 or even higher amidst new developments.

The stock is displaying significant technical strength, with expanding volume and breaking out of a long downtrend, signaling renewed buying interest.

Current Price	$52.00
Prev Close	$43.00
Open	$43.50
Dividend Yield	0.00%
50-Day Moving Average	$30.22
Beta	1.28
Avg. Volume	10.18M
PE Ratio	-6.18

52-Week High	$50.00
52-Week Low	$22.28
Market Capitalization	$16.8B
EPS (Annual)	-$9.27
Price to Book	2.09
Revenue Per Employee	$557,931.03
Enterprise Value/EBITDA	N/A

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRNA News

MRNAModerna Inc